“…These markers included CCR7, a chemokine receptor involved in T cell homing following antigen stimulation, CD69, an early activation marker necessary for Th17 differentiation, and the leukocyte adhesion molecule, CD44. Interestingly, changes to these markers, as well as genes involved in DNA damage, cell proliferation, and growth factor production, were detected in genetically-modified T cells as a result of electroporation and dramatically reduced their capacity to suppress tumor growth in vivo 11,13 . Collectively, our results indicate the μVS -based delivery does not perturb the native state of transfected cells, highlighting its potential to maintain the functionality and desired therapeutic effects of engineered cells upon administration.…”